Takhzyro Approved in China for Routine Prevention of HAE Attacks
News
Takeda’s Takhzyro (lanadelumab) has been approved in China for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, the company announced. It now becomes ... Read more